-
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
•
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation (ODD) status for its pipeline drug candidate CAN106, a long-acting monoclonal antibody (mAb) targeting C5 of the complement system, for use in myasthenia gravis (MG). Myasthenia gravis is a rare and chronic autoimmune disease caused…
-
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
•
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The collaboration aims to advance the development and application of automated high-throughput synthesis technology, project undertaking and delivery, and the design and construction of a new compound library. Financial details of the partnership were not disclosed.…
-
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States, and China, has announced the establishment of a new wholly-owned subsidiary, Nona Biosciences. The new unit will provide R&D solutions to clients for next-generation antibodies and other biotherapeutic development, covering the entire spectrum from discovery…
-
Novartis Considers Sale of Non-Core Units to Fund Innovation
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’ business units, according to unnamed insider sources cited by Bloomberg. The move aims to raise funds to support further innovation in core areas. The company is said to be evaluating its options for its respiratory…
-
Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into a cooperation intention agreement with Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The deal will lead to the introduction of Illumina’s latest NovaSeq X high throughput sequencer series products. Financial details…
-
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for its in-house developed oral programmed-death ligand 1 (PD-L1) small molecule inhibitor ASC61. This approval will accelerate the global development of the drug, which is currently…
-
MicroTech Medical Plans IPO on Shanghai’s STAR Market
•
China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct an initial public offering (IPO) of 93.46 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing price remains unknown at this stage. Company ProfileFounded in 2011, MicroTech Medical specializes in diabetes…
-
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate (ADC) SKB264, targeting trophoblast cell-surface antigen 2 (TROP2), has obtained approval from the National Medical Products Administration (NMPA) to enter a Phase II clinical study in advanced or metastatic non-small cell lung cancer (NSCLC). The…
